Pharma News

Hallucinogenic drug psilocybin eases existential anxiety in people with life-threatening cancer

  • Posted on: 1 December 2016
  • By: PharmaTutor News

In a small double-blind study, Johns Hopkins researchers report that a substantial majority of people suffering cancer-related anxiety or depression found considerable relief for up to six months from a single large dose of psilocybin -- the active compound in hallucinogenic "magic mushrooms."


The Bitter Truth About Sugar

  • Posted on: 30 November 2016
  • By: PharmaTutor News

On average, an individual having three square meals a day consumes up to 148 grams of sugar. Today, sugar is a pervasive element of our diet in spite of it being linked to various heart diseases as well as an increased risk of diabetes. The World Health Organization recommends cutting down on sugars to not more than 5% of total  daily calorie consumption, or a few teaspoons in contrast to the excessive amounts the average individual tends to consume on a daily basis.


PhaseRx get US FDA orphan drug status for PRX-OTC to treat ornithine transcarbamylase deficiency

  • Posted on: 30 November 2016
  • By: Shalini.Sharma

PhaseRx, Inc., a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, announced that its lead candidate, PRX-OTC, which is being developed for the treatment of ornithine transcarbamylase deficiency (OTCD), has received orphan drug designation by the US Food and Drug Administration (FDA).


German Merck and Pfizer receive Priority Review BLA for Avelumab from FDA

  • Posted on: 30 November 2016
  • By: Shalini.Sharma

EMD Serono Inc., the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. announced that the US Food and Drug Administration (FDA) has accepted for Priority Review EMD Serono's Biologics License Application (BLA) for avelumab. This review relates to avelumab's proposed use in patients with metastatic Merkel cell carcinoma (MCC), based on tumor response results from the JAVELIN Merkel 200 trial. Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and could be the first treatment indicated for metastatic MCC in the US, if approved. MCC is a rare and aggressive skin cancer, which impacts approximately 2,500 Americans a year.


ARIAD get USFDA Full Approval and Label Update for Iclusig® (ponatinib)

  • Posted on: 30 November 2016
  • By: Shalini.Sharma

ARIAD Pharmaceuticals, Inc.  announced that the U.S. Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) full approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated; and for the treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I positive Ph+ ALL. Iclusig was initially approved in December 2012 under the FDA’s accelerated approval program, which provides patients earlier access to promising new drugs that treat serious conditions based on a surrogate endpoint while the company conducts additional studies to confirm the drug’s clinical benefit. The therapy was granted the FDA’s orphan drug designation because it is intended to treat a rare disease or condition.


Proceedings of ISPOR India Andhra Pradesh Regional Chapter: 8TH National Symposium on Pharmacoeconomics & Outcomes Research

  • Posted on: 29 November 2016
  • By: PharmaTutor News

International Society for Pharmacoeconomics and Outcomes Research ISPOR India –Andhra Pradesh Regional Chapter in association with Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Andhra Pradesh; Rural Development Trust (RDT) Hospital, Anantapuramu, Andhra Pradesh and Indian Pharmaceutical Association (IPA) Anantapuramu Local Branch organized One Day National Symposium on “Innovations in Pharmacovigilance for ensuring Drug Safety and ensuring Life” on 24th November 2016 (Thursday)  at A.C auditorium, Rural Development Trust (RDT) Hospital, Anantapuramu, Andhra Pradesh.


Proceedings of Two Days Workshop on ADVANCES IN PHARMACY PRACTICE: A SERIES OF EDUCATIONAL and TRAINING MODULE

  • Posted on: 29 November 2016
  • By: PharmaTutor News

Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Andhra Pradesh in association with Priyadarshini Institute of Pharmaceutical Education and Research, Guntur. Andhra Pradesh organized a Two Days National Workshop on Advances in Pharmacy Practice: Series of Educational and Training Module by faculties of Division of Pharmacy Practice, Raghavendra Institute of Pharmaceutical Education and Research (RIPER).  The workshop drew around 60 Pharm. D students, which focussed on Patient care and the role of Pharmacists in healthcare system on policy and practice perspective.


Sun Pharma to acquire Biosintez in Russia

  • Posted on: 28 November 2016
  • By: Shalini.Sharma

Sun Pharma announced the execution of definitive agreements by its wholly owned subsidiary, for the acquisition of 85.1% of JSC Biosintez, a Russian pharmaceutical company engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region. The equity consideration for the 85.1% stake is US$ 24 million. Sun Pharma would also assume a debt of approximately US$ 36 million as part of this transaction.


Proteros enter into second oncology with Merck on epigenetic target

  • Posted on: 28 November 2016
  • By: Shalini.Sharma

Proteros biostructures GmbH announced that the company has entered into a second research agreement with Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, USA (known as MSD outside the US and Canada). The new collaboration is aimed at developing small molecule compounds against an additional epigenetic target for the potential treatment of various cancers.


Pages